Get the Daily Brief
Latest Biotech News
AI multiomics model improves personalized cardiovascular risk prediction
A study in Nature Communications led by Luo, Zhang, and Yang demonstrated that AI‑driven integration of multiomics datasets substantially enhanced individualized cardiovascular disease (CVD) risk...
Johns Hopkins blood test detects early cancers via epigenetic instability
Researchers at Johns Hopkins Kimmel Cancer Center unveiled a liquid‑biopsy approach that measures epigenetic variability—random fluctuations in DNA methylation patterns—to detect early‑stage...
AAV‑delivered UGA suppressor tRNA enables disease‑agnostic in vivo therapy
A Nature Biotechnology report described engineering an AAV‑deliverable suppressor tRNA that reads through UGA stop codons in vivo, presenting a potentially disease‑agnostic strategy for treating...
Protein language models reprogram CRISPR PAMs: broader editing access
Two Nature Biotechnology papers reported computational and experimental platforms that use protein language models to predict and reprogram protospacer adjacent motif (PAM) specificity of...
Genentech licenses SanegeneBio RNAi program: $200M upfront, up to $1.5B
Genentech struck an exclusive global license with SanegeneBio to develop and commercialize an undisclosed RNA interference (RNAi) program, paying $200 million up front and up to $1.5 billion in...
Novo’s CagriSema edges out semaglutide in phase 3 diabetes readouts
Novo Nordisk reported Phase 3 data showing its combo GLP‑1/amylin candidate CagriSema reduced blood glucose and body weight more than semaglutide (Wegovy) in a large type 2 diabetes trial. In...
Natera files Signatera MRD CDx to FDA for bladder cancer approval
Natera submitted a premarket approval (PMA) application to the FDA for Signatera CDx as a companion diagnostic to guide adjuvant atezolizumab (Tecentriq) in muscle‑invasive bladder cancer. The...
Hopkins unveils blood test for early cancers using epigenetic instability
Researchers at Johns Hopkins Kimmel Cancer Center introduced a liquid‑biopsy approach that detects early‑stage cancers by measuring epigenetic instability—random fluctuations in DNA...
In vivo CAR‑T reduces liver fibrosis in preclinical MASH models
Scientists at the Icahn School of Medicine at Mount Sinai reported that CAR‑T cells generated in vivo—designed to eliminate fibroblast activation protein (FAP)‑expressing stellate...
FDA urges long‑term follow‑up for CAR‑T use in autoimmune disease
Senior FDA officials, including Vinay Prasad of CBER, published recommendations urging drug developers to conduct long‑term monitoring when using CAR‑T therapies to treat autoimmune conditions....
PacBio sells short‑read assets to Illumina for $48.1M — sharp strategic shift
Pacific Biosciences sold select short‑read sequencing intellectual property and related assets to Illumina for $48.1 million, signaling PacBio’s renewed focus on long‑read sequencing and optics...
FDA opens PreCheck pilot to speed US prescription drug manufacturing builds
The U.S. Food and Drug Administration launched its PreCheck pilot program, accepting applications from biopharma companies seeking to relocate or build prescription drug manufacturing facilities...
University of Pittsburgh releases HemoLens: open‑source hemodynamics tool
Researchers at the University of Pittsburgh unveiled HemoLens, an open‑source platform designed to assess vascular hemodynamics at a fraction of the cost of commercial systems. HemoLens aims to...
AI mammography reduces interval cancers 12% in 100,000‑woman Lancet trial
A randomized study published in The Lancet tested ScreenPoint Medical’s Transpara Detection AI in breast‑cancer screening for over 100,000 women and found a 12% reduction in interval cancers...
Novo’s CagriSema Beats Semaglutide: Phase 3 Diabetes Readout
Novo Nordisk reported Phase 3 results showing its next‑generation metabolic combination, CagriSema (semaglutide + cagrilintide), reduced blood sugar and produced greater weight loss than...
MGI Acquires BGI Spatial and Nanopore Units: Sequencing Consolidation
MGI Tech filed disclosures that it will acquire two BGI Group spinouts—STOmics (spatial biology Stereo‑Seq commercialization) and CycloneSeq (BGI nanopore platforms)—for RMB 365.7 million (~$52.6...
Johns Hopkins Tests Epigenetic Instability to Spot Early Cancers
Researchers at Johns Hopkins Kimmel Cancer Center published a liquid‑biopsy approach that measures epigenetic variability—random fluctuations in DNA methylation—to detect early‑stage cancers....
MIT Unveils Portable Ultrasound: Aiming at Earlier, More Accessible Breast Screening
MIT researchers revealed a compact ultrasound system designed to make breast imaging more portable and accessible for higher‑risk populations. The platform combines a small probe with a data...
Natera Files Signatera PMA: MRD Companion Diagnostic for Bladder Cancer
Natera submitted a premarket approval (PMA) application to the US Food and Drug Administration for its Signatera CDx circulating tumor DNA assay as a companion diagnostic to guide adjuvant use of...
Sanegene’s RNAi Chemistry Attracts Big Pharma: $200M Upfront Deals
SanegeneBio agreed commercial licenses with major pharma players for RNAi assets, with Genentech (Roche) paying $200 million upfront for at least one candidate and larger potential milestone...